September 5, 2024, Taipei—Lotus Pharmaceutical Co., Ltd ("Lotus" or "the Company," Taiwan TWSE ticker: 1795) a multinational pharmaceutical company, today announced that its Board of Directors has approved the acquisition of the trademark, marketing authorization, and manufacturing know-how of Alpha Choay® in Vietnam and Cambodia from Sanofi. Immediately upon closing the transaction, the Company will take over Alpha Choay® business in Vietnam and Cambodia.
Alpha Choay® (Chymotrypsine) is an established and widely used treatment prescribed for edema caused by inflammation, trauma, surgery, or burns in Vietnam. It possesses effective anti-inflammatory properties that accelerate the reabsorption of inflammatory edemas, as well as postoperative and post-traumatic hematomas and edemas. The sales of Alpha Choay® in Vietnam & Cambodia marked more than US$22 million in 2023.
Petar Vazharov, Chief Executive Officer of Lotus, said: “Lotus is committed to providing patient access to quality medicines worldwide. The acquisition of Alpha Choay®, a leading brand in the anti-inflammatory sector in Vietnam underpins this commitment. Notably, Alpha Choay® offers Lotus access to the pharmacy channel in Vietnam whilst significantly expanding our presence in the region.”
Alpha Choay® marks the second acquisition by Lotus in Southeast Asia in 2024. The company is aggressively pursuing growth opportunities in the region to create scale, advancing towards its aspiration of becoming a leading player in the Asia-Pacific region.
About Lotus
Founded in 1966, Lotus (1795: TT) is a global pharmaceutical company focused on novel and generic drugs, providing better, safer, and more accessible medicines. With a top-tier R&D and manufacturing platform in Asia, Lotus has partnerships in major markets including the U.S., Europe, Japan, China, and Brazil. The company manages over 100 strategic projects in Asia and the US, with a portfolio exceeding 250 commercial products. Lotus invests in a diverse portfolio of high-barrier oncology treatments, complex generics, 505(b)(2), and NCE drugs through internal R&D and licensing. It also strengthens its competitiveness with biosimilars, supported by strategic partners. Its infrastructure is certified by leading regulatory authorities, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Inquiries:
Yu-ying Yang, Associate Director, Corporate communication.
+886 2 2700 5908
investor@lotuspharm.com